STX — Shield Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- £24.48m
- £36.35m
- £13.09m
Annual cashflow statement for Shield Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | C2021 December 31st | R2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8.8 | -2.63 | -19.7 | -49.8 | -33.3 |
| Depreciation | |||||
| Non-Cash Items | 0.254 | 1.24 | 0.41 | 19.1 | 2.84 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.86 | -2.71 | -1.2 | 9.98 | -7.74 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -4.07 | -1.4 | -18.3 | -18.1 | -37.1 |
| Capital Expenditures | -1.38 | -0.023 | -2.06 | -2.29 | -2.95 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.018 | 0.003 | 0.013 | 0.036 | 0.518 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.37 | -0.02 | -2.05 | -2.25 | -2.43 |
| Financing Cash Flow Items | -0.229 | -0.005 | -0.045 | -0.403 | -0.613 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.203 | -0.047 | 27.7 | 8.53 | 49.7 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -5.63 | -1.2 | 9.18 | -12.9 | 10.5 |